Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Advanced Hepatocellular Carcinoma

The goal of this clinical trial is to learn how well BGB-B2033 works and how safe it is in people with hepatocellular carcinoma (HCC) who have previously received up to two treatments that included programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) medicines. Researchers will compare BGB-B2033 with either sorafenib or lenvatinib chosen by the study doctor to see which treatment works better and is safer. The main questions it aims to answer are: * Does BGB-B2033 help control or slow the growth of liver cancer? * What medical problems or side effects do participants have

Trial Details

NCT ID
NCT07836530
Phase
PHASE3
Sponsor
BeOne Medicines
Status
RECRUITING
Cancer Type
Hepatocellular Carcinoma (HCC) Liver Cancer
Interventions
  • BGB-B2033
  • Lenvatinib
  • Sorafenib
Locations (sample)
  • South Brisbane, Queensland, Australia|-27.48034,153.02049
  • Grafton, Auckland, New Zealand|-36.86029,174.76566

Key Eligibility Criteria

  • Participants must have histologically confirmed Hepatocellular Carcinoma (HCC) that is not amenable to curative surgical or locoregional therapies.
  • Participants must have documented disease progression or intolerance after at least 1 but not exceeding 2 prior lines of systemic therapy containin…
  • Glypican-3 (GPC3) expression level must be known for stratification.
  • Participants must have at least 1 measurable lesion as assessed by RECIST v1.1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hepatocellular Carcinoma (HCC) Liver Cancer Trials on Trialify →